All In Biotech

Drug Trial Radar · NCT06680752

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

49

Planned (sponsor's estimate)

Start

May 20, 2025

Primary completion

Oct 2028

Study completion Dec 2028

Sponsor

Lead sponsor
ARCE Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.

Conditions

  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • MDS (Myelodysplastic Syndrome)

Interventions

  • ARD103Biological

    ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion

  • CyclophosphamideDrug

    iv administration for lymphodepletion

  • FludarabineDrug

    iv administration for lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 28 days post ARD103 infusion
  2. To determine the RP2D of ARD103Time frame: 28 days post ARD103 infusion
  3. To evaluate overall response rate (ORR)Time frame: Up to 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Novant Health Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Novant Health Cancer Institute

    Winston-Salem, North Carolina · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.